Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

KRN23

Aliases
Burosumab, Crysvita
Name
CRYSVITA
INN Name
Burosumab
FDA Approved
Yes

7 clinical trials

2 organizations

4 indications

1 document

Indication
Tumor-Induced Osteomalacia (TIO)
Indication
X-linked Hypophosphatemia
Indication
X-Linked Hypophosphatemia
Indication
X-linked hypophosphatemia
Clinical trial
An Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With Tumor-Induced Osteomalacia (TIO)
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Completed, Estimated PCD: 2018-11-30
Clinical trial
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia
Status: Completed, Estimated PCD: 2011-12-01
Clinical trial
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Completed, Estimated PCD: 2013-05-01
Clinical trial
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Completed, Estimated PCD: 2013-09-01
Document
DailyMed Label: CRYSVITA
Organization
Ultragenyx Pharmaceutical Inc.
Organization
Kyowa Kirin, Inc.